Amedisys, Tugaloo Home Health of Cumming and Hospice of NEGMC for all the exceptional love and care provided to Mr. McNeal and the entire family. Memorial Park Funeral Home, 2030 Memorial Park Rd., ...

However, UnitedHealth Group and Amedisys allege the lawsuit essentially ignores the companies' proposed divestiture package. The company didn’t identify which locations would be sold ...

Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ ... and Hollie Layfield of Macon, Ga. Home Health Social Worker/Therapists of the Year: Bruce Snow of Citronelle, Ala., ...

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the ...

UnitedHealth Group and Amedisys dropped their request to dismiss a government antitrust lawsuit over the insurer's proposed $3.3 billion acquisition of the home health provider. The companies said ...

Amedisys has a 1-year low of $82.15 and a 1-year high of $98.95. The company has a market cap of $3.03 billion, a PE ratio of 36.71, a price-to-earnings-growth ratio of 1.82 and a beta of 0.73.

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the ...

Amedisys, Inc. (NASDAQ:AMED – Free Report) – Research analysts at Leerink Partnrs cut their FY2024 earnings estimates for Amedisys in a note issued to investors on Wednesday, January 29th.

BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the ...

In a report released on January 29, Whit Mayo from Leerink Partners reiterated a Hold rating on Amedisys (AMED – Research Report), with a price target of $101.00. Whit Mayo has given his Hold ...

UnitedHealth Group says the Justice Department’s antitrust challenge to its proposed $3.3 billion purchase of Amedisys is wrong on the merits and threatens to deprive consumers of benefits from ...